ArticleCancer science2021
Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes.
Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 25 citations in OpenAlex.
- Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma.Discover oncology · 2026Review
- Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective.ImmunoTargets and therapy · 2026Review
- Photobiomodulation by infrared radiation on hallmarks of cancer.Lasers in medical science · 2025Review
- An Overview of Target Membrane Proteins for Near-Infrared Photoimmunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Effect of Fluence Rate on Tumor Tissue Damage in IRDye700DX-Based Photoimmunotherapy.Cancer medicine · 2025Article
- Article
- Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review.Cancer management and research · 2025Review
- Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.Antibody therapeutics · 2025Review
- Immunomodulatory effects of photothermal therapy in breast cancer: advances and challenges.Frontiers in immunology · 2025Review
- Evaluation of a Novel Lateral Emitting Laser Fiber for Near-Infrared Photoimmunotherapy.Cancers · 2024Article
- Article
- In vivo imaging of acute physiological responses after treatment of cancer with near-infrared photoimmunotherapy.Molecular imaging and biology · 2023Article
- Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives.Cancers · 2023Review
- Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer.International journal of cancer · 2023Article
- An Insight into Cholangiocarcinoma and Recent Advances in its Treatment.Journal of gastrointestinal cancer · 2023Review
- Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System.Pharmaceutics · 2023Review
- Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.International journal of molecular sciences · 2023Review
- Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective.Biomedicines · 2022Review
- Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment.View (Beijing, China) · 2022Article
- Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Near-infrared photoimmunotherapy (NIR-PIT) is a novel therapy for cancers that uses NIR light and antibody-photosensitizer (IR700) conjugates. However, it is difficult to deliver NIR light into the bile duct for cholangiocarcinoma (CCA) from the conventional extracorporeal apparatus. Thus, in this study, we developed a dedicated catheter with light emitting diodes (LEDs) that supersedes conventional external irradiation devices; we investigated the therapeutic effect of NIR-PIT for CCA using the novel catheter. The new catheter was designed to be placed in the bile duct and a temperature sensor was attached to the tip of the catheter to avoid thermal burn. An anti-epidermal growth factor receptor (EGFR) antibody, Panitumumab-IR700 conjugate or anti-human epidermal growth factor receptor type 2 (HER2) antibody, Trastuzumab-IR700 conjugate, was used with EGFR- or HER2-expressing cell lines, respectively. The in vitro efficacy of NIR-PIT was confirmed in cultured cells; the capability of the new catheter for NIR-PIT was then tested in a mouse tumor model. NIR-PIT via the developed catheter treated CCA xenografts in mice. NIR-PIT had an effect in Panitumumab-IR700 conjugate- and Trastuzumab-IR700 conjugate-treated CCA cells that depended on the receptor expression level. Tumor growth was significantly suppressed in mice treated with NIR-PIT using the novel catheter compared with controls (P < .01). NIR-PIT was an effective treatment for EGFR- and HER2-expressing CCA cells, and the novel catheter with mounted LEDs was useful for NIR-PIT of CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.